Basic demographic and behavioural characteristics of study population (n = 450:150 participants per arm).

aMetro = oral metronidazole 400 mg twice daily for 7 days,bclinda = one applicatorful of 2% vaginal clindamycin cream nightly for 7 nights,cplacebo and probiotic = vaginal pessary for 12 nights,dAus/UK ethnicity = identify as either Australian or British, other ethnicity comprised predominantly of individuals from South East Asia, China, Northern Europe and North America,ehormonal contraception = oral contraceptive pill, implants such as implanon, Depo-Provera® and hormonal rings such as Nuvaring®, MSP = male sexual partner, FSP = female sexual partner, RSP = regular sexual partner. Missing data for specific variables for ≤5% of participants. Missing data excluded from the analysis and proportions are calculated from available data. Proportion with missing data did not differ between arms.

aMetro：口服甲硝唑（metronidazole）400mg，每日2次，连续给药7天；bclinda：2%克林霉素阴道乳膏（vaginal clindamycin cream）每晚使用1支给药剂量，连续7晚；cplacebo and probiotic：安慰剂联合益生菌阴道栓剂（vaginal pessary），连续使用12晚；dAus/UK ethnicity：种族归属为澳大利亚裔或英国裔，其余种族受试者主要来自东南亚、中国、北欧及北美；ehormonal contraception：激素避孕方式，包括口服避孕药、依托孕烯植入剂（implanon）、醋酸甲羟孕酮避孕针（Depo-Provera®）以及阴道避孕环（Nuvaring®）；MSP：男性性伴侣（male sexual partner），FSP：女性性伴侣（female sexual partner），RSP：固定性伴侣（regular sexual partner）。特定变量的缺失数据占所有受试者的比例≤5%，分析时已排除缺失数据，各组比例均基于有效数据计算，且各组间缺失数据占比无显著差异。